Ivosidenib for advanced chondrosarcoma with IDH1 mutation
Treatments studied
Part of Cancer clinical trials.
This trial tests an experimental drug called ivosidenib for people with a specific type of bone cancer (chondrosarcoma) that has spread or can't be removed with surgery. The drug targets a genetic change (IDH1 mutation) found in some chondrosarcomas. It may help slow or stop tumor growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have chondrosarcoma (grade 1, 2, or 3) that has spread or is too advanced for surgery.
- Your tumor has a specific gene change called an IDH1 mutation (tested on a recent biopsy sample).
- You have had 0 or 1 prior drug treatments for advanced chondrosarcoma.
- Your disease has gotten worse (grown or come back) within the last year based on scans.
- You must be able to swallow pills and have no active brain metastases requiring high-dose steroids.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of three drugs (ivosidenib, durvalumab, and gemcitabine/cisplatin) as a first treatment for people with advanced bile duct cancer that has a specific IDH1 gene mutation. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests a targeted pill called ivosidenib for people with a specific type of bile duct cancer (IDH1-mutated) who have completed surgery and chemotherapy. The goal is to see if taking ivosidenib as a maintenance therapy helps keep the cancer from coming back.
This trial tests the drug Ivosidenib for people with advanced bile duct cancer that has a specific genetic change called an IDH1 mutation. It may be an option if you haven't had chemotherapy yet or if your cancer returned more than 6 months after surgery.
This study is looking at how well the drug ivosidenib works for people with a certain type of bile duct cancer (cholangiocarcinoma) that has a specific change in the IDH1 gene. It is for people whose cancer has spread or cannot be removed by surgery and who have already tried at least one other cancer treatment.
This trial tests an oral drug (ivosidenib) for people with IDH1-mutated cancers who also have liver or kidney problems. It aims to find the right dose and see how safe and effective it is for these patients.
This trial tests whether taking ivosidenib as a maintenance drug (to keep the cancer in remission) works better than standard care for patients with IDH1-mutated AML or high-risk MDS who cannot undergo a bone marrow transplant. Ivosidenib is a targeted drug that blocks a specific mutation found in your cancer.
Hear when a new Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.